Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

Journal of Hepatology

Volumn 60, Issue 6, 2014, Pages 1310-1324

  Jalan, Rajiv ^a   Fernandez, Javier ^b   Wiest, Reiner ^c   Schnabl, Bernd ^d   Moreau, Richard ^e   Angeli, Paolo ^f   Stadlbauer, Vanessa ^g   Gustot, Thierry ^h   Bernardi, Mauro ⁱ   Canton, Rafael ^j   Albillos, Agustin ^j   Lammert, Frank ^k   Wilmer, Alexander ^l   Mookerjee, Rajeshwar ^a   Vila, Jordi ^b   Garcia Martinez, Rita ^b   Wendon, Julia ^m   Such, José ^n,s   Cordoba, Juan ^o,s   Sanyal, Arun ^p   Garcia Tsao, Guadalupe ^q   Arroyo, Vicente ^b   Burroughs, Andrew ^r   Ginès, Pere ^b   more..

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITY OF PADOVA   (Italy)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h ERASME HOSPITAL   (Belgium)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k SAARLAND UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m KING S COLLEGE HOSPITAL   (United Kingdom)

ⁿ MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^o HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^p VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^q YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY COLLEGE LONDON   (United Kingdom)

^s INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Bacterial infection; Cirrhosis; Diagnosis; Multiresistant bacteria

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; NORFLOXACIN; PROCALCITONIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ADRENAL INSUFFICIENCY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; BRAIN DYSFUNCTION; CLINICAL FEATURE; COAGULATION FAILURE; COMMUNITY ACQUIRED INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EARLY DIAGNOSIS; GASTROINTESTINAL HEMORRHAGE; GENETIC PREDISPOSITION; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; INTESTINAL BARRIER DYSFUNCTION; INTESTINE FLORA; KIDNEY FAILURE; LIVER CIRRHOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIDRUG RESISTANCE; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; POPULATION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PSEUDOMONAS AERUGINOSA; RESUSCITATION; SEPSIS; SEPTIC SHOCK; STENOTROPHOMONAS MALTOPHILIA; STOMACH ACID SECRETION; TIGHT JUNCTION; TISSUE INJURY; VARIX BLEEDING; ANTIBIOTIC RESISTANCE; BLEEDING; INFECTION PREVENTION; BACTERIAL INFECTIONS; COMPLICATION; CONSENSUS DEVELOPMENT; GASTROENTEROLOGY; MICROBIOLOGY; PRACTICE GUIDELINE; STANDARDS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; GASTROENTEROLOGY; HUMANS; LIVER CIRRHOSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84901193937     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.01.024     Document Type: Note

References (162)

1. J. Fernandez, and T. Gustot Management of bacterial infections in cirrhosis J Hepatol 56 2012 S1 S12
2. T. Gustot, F. Durand, D. Lebrec, J.L. Vincent, and R. Moreau Severe sepsis in cirrhosis Hepatology 50 2009 2022 2033
3. J. Fernandez, M. Navasa, J. Gomez, J. Colmenero, J. Vila, and V. Arroyo et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis Hepatology 35 2002 140 148
4. J. Fernández, J. Acevedo, M. Castro, O. Garcia, C.R. de Lope, and D. Roca et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study Hepatology 55 2012 1551 1561
5. M.G. Foreman, D.M. Mannino, and M. Moss Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey Chest 124 2003 1016 1020
6. V. Arvaniti, G. D'Amico, G. Fede, P. Manousou, E. Tsochatzis, and M. Pleguezuelo et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis Gastroenterology 139 2010 1246 1256
7. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 18 2012 268 281
8. N. Woodford, J.F. Turton, and D.M. Livermore Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance FEMS Microbiol Rev 35 2011 736 755
9. M. Merli, C. Lucidi, V. Giannelli, M. Giusto, O. Riggio, and M. Falcone et al. Cirrhotic patients are at risk for health care-associated bacterial infections Clin Gastroenterol Hepatol 8 2010 979 985
10. J.Y. Song, S.J. Jung, C.W. Park, J.W. Sohn, W.J. Kim, and M.J. Kim et al. Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial vs. community acquired J Korean Med Sci 21 2006 666 671
11. F. Cereto, X. Herranz, E. Moreno, A. Andreu, M. Vergara, and D. Fontanals et al. Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis Eur J Gastroenterol hepatol 20 2008 924 929
12. S. Angeloni, C. Leboffe, A. Parente, M. Venditti, A. Giordano, and M. Merli et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice World J Gastroenterol 14 2008 2757 2762
13. H.S. Cheong, C. Kang, J.A. Lee, S.Y. Moon, M.K. Joung, and D.R. Chung et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis CID 48 2009 1230 1236
14. K.H. Song, J.H. Jeon, W.B. Park, S.W. Park, H.B. Kim, and M.D. Oh et al. Clinical outcomes of spontaneous bacterial peritonitis due to extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study BMC Infect Dis 9 2009 41 46
15. J. Heo, Y.S. Seo, H.J. Yim, T. Hahn, S.H. Park, and S.H. Ahn et al. Clinical features and prognosis of spontaneous bacterial peritonitis in Korean patients with liver cirrhosis: a multicenter retrospective study Gut Liver 3 2009 197 204
16. T. Yakar, M. Güçlü, E. Serin, H. Alişkan, and E. Husamettin A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis Dig Dis Sci 55 2009 1149 1154
17. L. Piroth, A. Pechinot, A. Minello, B. Jaulhac, I. Patry, and T. Hadou et al. Bacterial epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study Scand J Infect Dis 37 2009 2 8
18. A. Umgelter, W. Reindl, M. Miedaner, R.M. Schmid, and W. Huber Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis Infection 37 2009 2 8
19. X. Ariza, J. Castellote, J. Lora-Tamayo, A. Girbau, S. Salord, and R. Rota et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis J Hepatol 56 2012 825 832
20. P. Tandon, A. Delisle, J.E. Topal, and G. Garcia-Tsao High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center Clin Gastroenterol Hepatol 10 2012 1291 1298
21. J. Acevedo, A. Silva, V. Prado, and J. Fernandez The new epidemiology of nosocomial bacterial infections in cirrhosis: therapeutical implications Hepatol Int 7 2013 72 79
22. S. Piano, A. Romano, S. Rosi, A. Gatta, and P. Angeli Spontaneous bacterial peritonitis due to carbapenemase-producing Klebsiella pneumoniae: the last therapeutic challenge Eur J Gastroenterol Hepatol 24 2012 1234 1237
23. B. Campillo, J.P. Richardet, T. Kheo, and C. Dupeyron Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection CID 35 2002 1 10
24. F. Bert, M. Andreu, F. Durand, F. Degos, J.O. Galdbart, and R. Moreau et al. Nosocomial and community-acquired spontaneous bacterial peritonitis: comparative microbiology and therapeutic implications Eur J Clin Microbiol Infect Dis 22 2003 10 15
25. R.D. Berg, and A.W. Garlington Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model Infect Immun 23 1979 403 411
26. L.V. Hooper, D.R. Littman, and A.J. Macpherson Interactions between the microbiota and the immune system Science 336 2012 1268 1273
27. D.R. Littman, and E.G. Pamer Role of the commensal microbiota in normal and pathogenic host immune responses Cell Host Microbe 20 2011 311 323
28. T.M. Bauer, B. Steinbruckner, F.E. Brinkmann, A.K. Ditzen, H. Schwacha, and J.J. Aponte et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis Am J Gastroenterol 96 2001 2962 2967
29. F.C. Morencos, C.G. las Heras, R.L. Martin, M.J. Lopez Arias, F. Ledesma, and R.F. Pons Small bowel bacterial overgrowth in patients with alcoholic cirrhosis Dig Dis Sci 40 1995 1252 1256
30. C. Pande, A. Kumar, and S.K. Sarin Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease Aliment Pharmacol Ther 29 2009 1273 1281
31. C.S. Chang, G.H. Chen, H.C. Lien, and H.Z. Yeh Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis Hepatology 28 1998 1187 1190
32. G. Zhao, M. Downes, R.T. Yu, J.M. Shelton, J.A. Richardson, and J.J. Repa et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor Proc Natl Acad Sci U S A 103 2006 3920 3925
33. M. Perez-Paramo, J. Munoz, A. Albillos, I. Freile, F. Portero, and M. Santos et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites Hepatology 31 2000 43 48
34. M. Shindo, A. Ken, and T. Okuno Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy Cancer 85 1999 1943 1950
35. Z. Teltschik, R. Wiest, J. Beisner, S. Nuding, C. Hofmann, and J. Schoelmerich et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense Hepatology 55 2012 1154 1163
36. A.W. Yan, D.E. Fouts, J. Brandl, P. Starkel, M. Torralba, and E. Schott et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease Hepatology 53 2011 96 105
37. S.N. Lichtman, R.B. Sartor, J. Keku, and J.H. Schwab Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth Gastroenterology 98 1990 414 423
38. E. Seki, S. De Minicis, C.H. Osterreicher, J. Kluwe, Y. Osawa, and D.A. Brenner et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis Nat Med 13 2007 1324 1332
39. Y. Adachi, B.U. Bradford, W. Gao, H.K. Bojes, and R.G. Thurman Inactivation of Kupffer cells prevents early alcohol-induced liver injury Hepatology 20 1994 453 460
40. G.N. Kalambokis, and E.V. Tsianos Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis Hepatology 55 2012 655 656
41. A.M. Madrid, C. Hurtado, M. Venegas, F. Cumsille, and C. Defilippi Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function Am J Gastroenterol 96 2001 1251 1255
42. B. Leber, W. Spindelboeck, and V. Stadlbauer Infectious complications of acute and chronic liver disease Semin Respir Crit Care Med 33 2012 80 95
43. J.S. Bajaj, P.B. Hylemon, J.M. Ridlon, D.M. Heuman, K. Daita, and M.B. White et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation Am J Physiol Gastrointest Liver Physiol 303 2012 G675 G685
44. Y. Chen, F. Yang, H. Lu, B. Wang, Y. Chen, and D. Lei et al. Characterization of fecal microbial communities in patients with liver cirrhosis Hepatology 54 2011 562 572
45. S. Vaishnava, M. Yamamoto, K.M. Severson, K.A. Ruhn, X. Yu, and O. Koren et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine Science 334 2011 255 258
46. E.A. Mutlu, P.M. Gillevet, H. Rangwala, M. Sikaroodi, A. Naqvi, and P.A. Engen et al. Colonic microbiome is altered in alcoholism Am J Physiol Gastrointest Liver Physiol 302 2012 G966 G978
47. P.J. Du, H. Vanheel, C.E. Janssen, L. Roos, T. Slavik, and P.I. Stivaktas et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function J Hepatol 58 2013 1125 1132
48. S. Yoshimoto, T.M. Loo, K. Atarashi, H. Kanda, S. Sato, and S. Oyadomari et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome Nature 499 2013 97 101
49. S.F. Assimakopoulos, A.C. Tsamandas, G.I. Tsiaoussis, E. Karatza, C. Triantos, and C.E. Vagianos et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability Eur J Clin Invest 42 2012 439 446
50. S.F. Assimakopoulos Uncovering the molecular events associated with increased intestinal permeability in liver cirrhosis: the pivotal role of enterocyte tight junctions and future perspectives J Hepatol 59 2013 1144 1146
51. J. Genesca, R. Marti, F. Rojo, F. Campos, V. Peribanez, and A. Gonzalez et al. Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites Gut 52 2003 1054 1059
52. L. Munoz, A. Albillos, M. Nieto, E. Reyes, L. Lledo, and J. Monserrat et al. Mesenteric Th1 polarization and monocyte TNF-alpha production: first steps to systemic inflammation in rats with cirrhosis Hepatology 42 2005 411 419
53. O. Saitoh, K. Sugi, K. Lojima, H. Matsumoto, K. Nakagawa, and M. Kayazawa et al. Increased prevalence of intestinal inflammation in patients with liver cirrhosis World J Gastroenterol 5 1999 391 396
54. V. Lorenzo-Zuniga, R. Bartoli, R. Planas, A.F. Hofmann, B. Vinado, and L.R. Hagey et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats Hepatology 37 2003 551 557
55. S.M. Man, N.O. Kaakoush, and H.M. Mitchell The role of bacteria and pattern-recognition receptors in Crohn's disease Nat Rev Gastroenterol Hepatol 8 2011 152 168
56. E. Holler, G. Rogler, H. Herfarth, J. Brenmoehl, P.J. Wild, and J. Hahn et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation Blood 104 2004 889 894
57. J. Brenmoehl, H. Herfarth, T. Gluck, F. Audebert, S. Barlage, and G. Schmitz et al. Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients Intensive Care Med 33 2007 1541 1548
58. Z. Ben Ari, O. Avias, O. Pappo, V. Zilbermints, Y. Cheporko, and L. Bachmetov et al. Reduced hepatic injury in Toll-like receptor 4-deficient mice following d-galactosamine/lipopolysaccharide-induced fulminant hepatic failure Cell Physiol Biochem 29 2012 41 50
59. N. Shah, M. Montes de Oca, M. Jover-Cobos, K. Tanamoto, M. Muroi, and K. Sugiyama et al. Role of toll-like receptor 4 in mediating multi-organ dysfunction in mice with acetaminophen induced acute liver failure Liver Transpl 19 2013 751 761
60. B. Appenrodt, F. Grunhage, M.G. Gentemann, L. Thyssen, T. Sauerbruch, and F. Lammert Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis Hepatology 51 2010 1327 1333
61. T. Bruns, J. Peter, P.A. Reuken, D.H. Grabe, S.R. Schuldes, and J. Brenmoehl et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis Liver Int 32 2012 223 230
62. H.D. Nischalke, C. Berger, K. Aldenhoff, L. Thyssen, M. Gentemann, and F. Grunhage et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis J Hepatol 55 2011 1010 1016
63. G. Soriano, E. Sanchez, J. Nieto, E. Roman, S. Vidal, and L. Oliva et al. Cytokine production in patients with cirrhosis and D299G and/or TLR4 polymorphisms J Hepatol 58 Suppl. 1 2013 S247 S248
64. G. Tritto, Z. Bechlis, V. Stadlbauer, N. Davies, R. Frances, and N. Shah et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis J Hepatol 55 2011 574 581
65. H.E. Wasmuth, D. Kunz, E. Yagmur, A. Timmer-Stranghoner, D. Vidacek, and E. Siewert et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis J Hepatol 42 2005 195 201
66. R. Malik, R.P. Mookerjee, and R. Jalan Infection and inflammation in liver failure: two sides of the same coin J Hepatol 51 2009 426 429
67. H. Doi, T.K. Iyer, E. Carpenter, H. Li, K.M. Chang, and R.H. Vonderheide et al. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population Hepatology 55 2012 709 719
68. Z. Tian, Y. Chen, and B. Gao Natural killer cells in liver disease Hepatology 57 2013 1654 1662
69. M. Lario, L. Munoz, M. Ubeda, M.J. Borrero, J. Martinez, and J. Monserrat et al. Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis J Hepatol 59 2013 723 730
70. F.J. Laso, J.I. Madruga, J.A. Giron, A. Lopez, J. Ciudad, and J.F. San Miguel et al. Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption Hepatology 25 1997 1096 1100
71. B. Gao, W.I. Jeong, and Z. Tian Liver: an organ with predominant innate immunity Hepatology 47 2008 729 736
72. A. Albillos, A.D.L. Hera, E. Reyes, J. Monserrat, L. Munoz, and M. Nieto et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin J Hepatol 40 2004 624 631
73. L. Munoz, B.M. Jose, M. Ubeda, M. Lario, D. Diaz, and R. Frances et al. Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis Hepatology 56 2012 1861 1869
74. R. Jalan, P. Gines, J. Olson, R. Mookerjee, R. Moreau, and G. Garcia-Tsao et al. Acute-on-chronic liver failure J Hepatol 57 2012 1336 1348
75. A. Plessier, M.H. Denninger, Y. Consigny, F. Pessione, C. Francoz, and F. Durand et al. Coagulation disorders in patients with cirrhosis and severe sepsis Liver Int 23 2003 440 448
76. R. Moreau, R. Jalan, P. Gines, M. Pavesi, P. Angeli, and J. Cordoba et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis Gastroenterology 144 2013 1426 1437
77. R. Medzhitov, D.S. Schneider, and M.P. Soares Disease tolerance as a defense strategy Science 335 2012 936 941
78. B. Byl, I. Roucloux, A. Crusiaux, E. Dupont, and J. Devière Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients Gastroenterology 104 1993 1492 1497
79. M. Navasa, A. Follo, X. Filella, W. Jiménez, A. Francitorra, and R. Planas et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality Hepatology 27 1998 1227 1232
80. J. Devière, J. Content, C. Denys, P. Vandenbussche, L. Schandene, and J. Wybran et al. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis Hepatology 11 1990 628 634
81. O. Le Moine, A. Marchant, D. De Groote, C. Azar, M. Goldman, and J. Devière Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis Hepatology 22 1995 1436 1439
82. K.A. Tazi, J.J. Quioc, V. Saada, A. Bezeaud, D. Lebrec, and R. Moreau Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M J Hepatol 45 2006 280 289
83. D. Thabut, J. Massard, A. Gangloff, N. Carbonell, C. Francoz, and E. Nguyen-Khac et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure Hepatology 46 2007 1872 1882
84. K.A. Tazi, J.J. Quioc, W. Abdel-Razek, Z. Tellier, C. Guichard, and E. Ogier-Denis et al. Protein array technology to investigate cytokine production by monocytes from patients with advanced alcoholic cirrhosis: an ex vivo pilot study Hepatol Res 39 2009 706 715
85. A. Galbois, D. Thabut, K.A. Tazi, M. Rudler, M.S. Mohammadi, and D. Bonnefont-Rousselot et al. Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis Hepatology 49 2009 175 184
86. N. Coant, M. Simon-Rudler, T. Gustot, M. Fasseu, S. Gandoura, and K. Ragot et al. Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in patients with decompensated cirrhosis J Hepatol 55 2011 784 793
87. S. Gandoura, E. Weiss, P.E. Rautou, M. Fasseu, T. Gustot, and F. Lemoine et al. Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis J Hepatol 58 5 2013 936 948
88. R. Moreau, E. Barrière, K.A. Tazi, B. Lardeux, D. Dargère, and W. Urbanowicz et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis Hepatology 36 2002 1070 1078
89. K.A. Tazi, I. Bièche, V. Paradis, C. Guichard, I. Laurendeau, and D. Dargère et al. In vivo altered unfolded protein response and apoptosis in livers from lipopolysaccharide-challenged cirrhotic rats J Hepatol 46 2007 1075 1088
90. D. Thabut, K.A. Tazi, D. Bonnefont-Rousselot, M. Aller, O. Farges, and M.C. Guimont et al. HDL administration attenuates liver proinflammatory response, restores liver eNOS activity and lowers portal pressure in cirrhotic rats Hepatology 46 2007 1893 1906
91. M.J. Ramírez, A. Ibáñez, M. Navasa, E. Casals, M. Morales-Ruiz, and W. Jiménez et al. High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites J Hepatol 40 2004 424 430
92. C. Terra, M. Guevara, A. Torre, R. Gilabert, J. Fernández, and M. Martín-Llahí et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score Gastroenterology 129 2005 1944 1953
93. P. Sort, M. Navasa, V. Arroyo, X. Aldeguer, R. Planas, and L. Ruiz-del-Arbol et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med 341 1999 403 409
94. J.M. Trawalé, V. Paradis, P.E. Rautou, C. Francoz, S. Escolano, and M. Sallée et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study Liver Int 30 2010 725 732
95. M. Merli, C. Lucidi, I. Pentassuglio, V. Giannelli, M. Giusto, and V. Di Gregorio et al. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections J Hepatol 59 2 2013 243 250
96. L. Chavarria, M. Oria, J. Romero-Giménez, J. Alonso, S. Lope-Piedrafita, and J. Cordoba Brain magnetic resonance in experimental acute-on-chronic liver failure Liver Int 33 2013 294 300
97. B. Bernard, J.D. Grangé, E.N. Khac, X. Amiot, P. Opolon, and T. Poynard Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis Hepatology 29 1999 1655 1661
98. J. Goulis, D. Patch, and A.K. Burroughs Bacterial infection in the pathogenesis of variceal bleeding Lancet 353 1999 139 142
99. G. Fede, L. Spadaro, T. Tomaselli, G. Privitera, G. Germani, and E. Tsochatzis et al. Adrenocortical dysfunction in liver disease: a systematic review Hepatology 55 2012 1282 1291
100. M.H. Tsai, Y.S. Peng, Y.C. Chen, N.J. Liu, Y.P. Ho, and J.T. Fang et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock Hepatology 43 2006 673 681
101. T. Thevenot, S. Borot, A. Remy-Martin, R. Sapin, J.P. Cervoni, and C. Richou et al. Assessment of adrenal function in cirrhotic patients using concentration of serum-free and salivary cortisol Liver Int 31 2011 425
102. T. Thevenot, R. Dorin, E. Monnet, C.R. Qualls, R. Sapin, and E. Grandclement et al. High serum levels of free cortisol indicate severity of cirrhosis in hemodynamically stable patients J Gastroenterol Hepatol 27 2012 1596 1601
103. J. Acevedo, J. Fernández, V. Prado, A. Silva, M. Castro, and M. Pavesi et al. Relative adrenal insufficiency in decompensated cirrhosis: relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death Hepatology 58 2013 1757 1765
104. S. Bhattacharya Early diagnosis of resistant pathogens: how can it improve antimicrobial treatment? Virulence 4 2013 172 184
105. R.C. Bone, R.A. Balk, F.B. Cerra, R.P. Dellinger, A.M. Fein, and W.A. Knaus et al. ACCP/SCCM Consensus Conference Committee Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992 Chest 136 2009 864 874
106. M. Cazzaniga, E. Dionigi, G. Gobbo, A. Fioretti, V. Monti, and F. Salerno The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome J Hepatol 51 2009 475 482
107. B.I. Kim, H.J. Kim, J.H. Park, D.I. Park, Y.K. Cho, and C.I. Sohn et al. Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage J Gastroenterol Hepatol 26 2011 550 557
108. J.P. Cervoni, T. Thévenot, D. Weil, M. Muel, O. Barbot, and F. Sheppard et al. C-reactive protein predicts short-term mortality in patients with cirrhosis J Hepatol 56 2012 1299 1304
109. F. Gundling, F. Schmidtler, A. Hapfelmeier, B. Schulte, T. Schmidt, and C. Pehl et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis Liver Int 31 2011 1406 1415
110. G. Pelletier, M. Brivet, M. Ducreux, M.J. Briantais, A. Lemonnier, and J.P. Etienne Is D-lactate assay useful for the diagnosis of ascitic infection in patients with liver cirrhosis? Gastroenterol Clin Biol 17 1993 304 305
111. A. Tas, E. Akbal, Y. Beyazit, and E. Kocak Serum lactate level predict mortality in elderly patients with cirrhosis Wien Klin Wochenschr 124 2012 520 525
112. P. Zapater, R. Frances, J.M. Gonzalez-Navajas, R. Moreu, L. Llanos, and D. Pascual et al. Presence of bacterial DNA is a new survival indicator in patients with cirrhosis and non-infected ascitic fluid Hepatology 46 2007 A40
113. B. Appenrodt, L.E. Lehmann, L. Thyssen, M. Gentemann, C. Rabe, and E. Molitor et al. Is detection of bacterial DNA in ascitic fluid of clinical relevance? Eur J Gastroenterol Hepatol 22 2010 1487 1494
114. R.P. Mookerjee, V. Stadlbauer, S. Lidder, G.A. Wright, S.J. Hodges, and N.A. Davies et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome Hepatology 46 2007 831 840 [Erratum in: Hepatology. 2007; 46: 205]
115. M.L. Berres, B. Schnyder, E. Yagmur, B. Inglis, S. Stanzel, and J.J. Tischendorf et al. Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis Liver Int 29 2009 536 543
116. C.Y. Lin, I.F. Tsai, Y.P. Ho, C.T. Huang, Y.C. Lin, and C.J. Lin et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis J Hepatol 46 2007 816 826
117. G. Holdstock, B. Leslie, S. Hill, A. Tanner, and R. Wright Monocyte function in cirrhosis J Clin Pathol 35 1982 972 979
118. F. Gomez, P. Ruiz, and A.D. Schreiber Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis N Engl J Med 331 1994 1122 1128
119. C. Gabay, and I. Kushner Acute-phase proteins and other systemic responses to inflammation N Engl J Med 340 1999 448 454
120. D. Peres Bota, M. Van Nuffelen, A.N. Zakariah, and J.L. Vincent Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver J Lab Clin Med 146 2005 347 351
121. W.B. Park, K.D. Lee, C.S. Lee, H.C. Jang, H.B. Kim, and H.S. Lee et al. Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis Diagn Microbiol Infect Dis 51 2005 227 230
122. A. Tsiakalos, A. Karatzaferis, P. Ziakas, and G. Hatzis Acute-phase proteins as indicators of bacterial infection in patients with cirrhosis Liver Int 29 2009 1538 1542
123. M. Papp, Z. Vitalis, I. Altorjay, I. Tornai, M. Udvardy, and J. Harsfalvi et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections Liver Int 32 2012 603 611
124. C.H. Li, R.B. Yang, J.H. Pang, S.S. Chang, C.C. Lin, and C.H. Chen et al. Procalcitonin as a biomarker for bacterial infections in patients with liver cirrhosis in the emergency department Acad Emerg Med 18 2011 121 126
125. C. Wacker, A. Prkno, F.M. Brunkhorst, and P. Schlattmann Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis Lancet Infect Dis 13 2013 426 435
126. P. Schuetz, W. Albrich, and B. Mueller Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future BMC Med 22 2011 107
127. A. Albillos, A. de-la-Hera, and M. Alvarez-Mon Serum lipopolysaccharide- binding protein prediction of severe bacterial infection in cirrhotic patients with ascites Lancet 363 2004 1608 1610
128. P.A. Reuken, M. Kiehntopf, A. Stallmach, and T. Bruns Mid-regional pro-adrenomedullin (MR-proADM): an even better prognostic biomarker than C-reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection? J Hepatol 57 2012 1156 1158
129. S. Sontakke, M.B. Cadenas, R.G. Maggi, P.P. Diniz, and E.B. Breitschwerdt Use of broad range16S rDNA PCR in clinical microbiology J Microbiol Methods 76 2009 217 225
130. S.K. Rampini, G.V. Bloemberg, P.M. Keller, A.C. Büchler, G. Dollenmaier, and R.F. Speck et al. Broad-range 16S rRNA gene polymerase chain reaction for diagnosis of culture-negative bacterial infections Clin Infect Dis 53 2011 1245 1251
131. J. Hardick, H. Won, K. Jeng, Y.H. Hsieh, C.A. Gaydos, and R.E. Rothman et al. Identification of bacterial pathogens in ascitic fluids from patients with suspected spontaneous bacterial peritonitis by use of broad-range PCR [16S PCR] coupled with high-resolution melt analysis J Clin Microbiol 50 2012 2428 2432
132. L. Pasqualini, A. Mencacci, C. Leli, P. Montagna, A. Cardaccia, and E. Cenci et al. Diagnostic performance of a multiple real-time PCR assay in patients with suspected sepsis hospitalized in an internal medicine ward J Clin Microbiol 50 2012 1285 1288
133. P. Espinal, H. Seifert, L. Dijkshoorn, J. Vila, and I. Roca Rapid and accurate identification of genomic species from the Acinetobacter baumannii [Ab] group by MALDI-TOF MS Clin Microbiol Infect 18 2012 1097 1103
134. Y.M. Arabi, S.I. Dara, Z. Memish, A.A. Abdulmajeed, H.M. Tamim, and N. Al-Shirawi et al. Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis Hepatology 56 2012 2305 2315
135. P. Ginès, P. Angeli, K. Lenz, S. Moller, K. Moore, and R. Moreau et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 2010 397 417
136. B.A. Runyon AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012 Hepatology 57 2013 1651 1653 [ http://www.aasld.org/practiceguidelines/Documents/ascitesupdate2013.pdf ]
137. J. Fernandez, and V. Arroyo Bacterial infections in cirrhosis - a growing problem with significant implications Clin Liver Dis 2 2013 102 105
138. A. Rimola, G. Garcia-Tsao, M. Navasa, L.J. Piddock, R. Planas, and B. Bernard et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International ascites club J Hepatol 32 2000 142 153
139. B.A. Runyon, J.G. McHutchison, M.R. Antillon, E.A. Akriviadis, and A.A. Montano Short-course vs. long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients Gastroenterology 100 1991 1737 1742
140. R. Garcia-Martinez, P. Caraceni, M. Bernardi, P. Gines, V. Arroyo, and R. Jalan Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications Hepatology 58 5 2013 1836 1846
141. M. Casas, G. Soriano, E. Ayala, C. Guarner-Argente, I. Ordas, and J. Merce et al. Intravenous albumin is not necessary in cirrhotic patients with spontaneous bacterial peritonitis and low-risk mortality J Hepatol 76 2007 S91
142. J. Fernandez, J. Monteagudo, X. Bargallo, W. Jimenez, J. Bosch, and V. Arroyo et al. A randomized unblinded pilot study comparing albumin vs. hydroxyethyl starch in spontaneous bacterial peritonitis Hepatology 42 2005 627 634
143. M. Guevara, C. Terra, A. Nazar, E. Sola, J. Fernandez, and M. Pavesi et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study J Hepatol 57 2012 759 765
144. R.P. Dellinger, M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, and S.M. Opal et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012 Crit Care Med 41 2013 580 637
145. P.E. Marik, S.M. Pastores, D. Annane, G.U. Meduri, C.L. Sprung, and W. Arlt et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine Crit Care Med 36 2008 1937 1949
146. J. Fernández, A. Escorsell, M. Zabalza, V. Felipe, M. Navasa, and A. Mas et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival Hepatology 44 2006 1288 1295
147. Y.M. Arabi, A. Aljumah, O. Dabbagh, H.M. Tamim, A.H. Rishu, and A. Al-Abdulkareem et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial CMAJ 182 2010 1971 1977
148. G. Soriano, C. Guarner, A. Tomás, C. Villanueva, X. Torras, and D. González et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal haemorrhage Gastroenterology 103 1992 1267 1272
149. C. Guarner, R. Sola, G. Soriano, M.T. Novella, M.C. Vila, and M. Sàbat et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic protein levels Gastroenterology 117 1999 414 419
150. M. Blaise, D. Pateron, J.C. Trinchet, S. Levacher, M. Beaugrand, and J.L. Pourriat Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal haemorrhage Hepatology 20 1994 34 38
151. N.C. Chavez-Tapia, T. Barrientos-Gutierrez, F.I. Tellez-Avila, K. Soares-Weiser, and M. Uribe Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding Cochrane Database Syst Rev 9 2010 CD002907
152. J. Fernandez, L. Ruiz del Arbol, C. Gomez, R. Durandez, R. Serradilla, and C. Guarner et al. Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage Gastroenterology 131 2006 1049 1056
153. R. de Franchis Baveno V faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 53 2010 762 768
154. J. Fernandez, N. Navasa, R. Planas, S. Montoliu, D. Monfort, and G. Soriano et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis Gastroenterology 133 2007 818 824
155. P. Ginés, A. Rimola, R. Planas, V. Vargas, F. Marco, and M. Almela et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial Hepatology 12 1990 716 724
156. H.L. Koo, and H.L. Dupont Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases Curr Opin Gastroenterol 26 2010 17 25
157. N.M. Bass, K.D. Mullen, A. Sanyal, F. Poordad, G. Neff, and C.B. Leevy et al. Rifaximin treatment in hepatic encephalopathy N Engl J Med 362 2010 1071 1081
158. M.A. Hanouneh, I.A. Hanouneh, J.G. Hashash, R. Law, J.M. Esfeh, and R. Lopez et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis J Clin Gastroenterol 46 2012 709 715
159. T. Reiberger, A. Ferlitsch, B.A. Payer, M. Mandorfer, B.B. Heinisch, and H. Hayden et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis J Hepatol 58 5 2013 911 921
160. M. Chiva, G. Soriano, I. Rochat, C. Peralta, F. Rochat, and T. Llovet et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis J Hepatol 37 2002 456
161. A. Pardo, R. Bartoli, V. Lorenzo-Zuniga, R. Planas, B. Vinado, and J. Riba et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis Hepatology 31 2000 858 863
162. T.M. Bauer, J. Fernández, M. Navasa, J. Vila, and J. Rodés Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis J Hepatol 36 2002 501 506